新闻稿：赛诺菲与再生元扩大全球联盟，推出多种下一代长效免疫学抗体-动脉网

Sanofi and Regeneron expand global Alliance with multiple next-generation, long-acting immunology antibodies

赛诺菲等信源发布 2026-10-01 13:14



可切换为仅中文







Sanofi and Regeneron expand global

赛诺菲与再生元拓展全球业务

Alliance with multiple nex

与多个节点结盟

t-generation, long-acting

长效t-代

immunology antibodies

免疫学抗体

REGN20423, a clinical-stage long-acting IL-13 monoclonal antibody invented and developed by Regeneron, is added to the Alliance, along with a long-acting IL-4xIL-13 bispecific and two other long-acting pre-clinical antibodies from Regeneron

由再生元（Regeneron）发明和开发的临床阶段长效IL-13单克隆抗体REGN20423，以及一种长效IL-4xIL-13双特异性抗体和另外两种来自再生元的长效临床前抗体，被纳入该联盟。

Regeneron to receive $1 billion upfront, with potential for up to an additional $7 billion in future milestone payments; companies to equally share development and commercialization costs, as well as any future profits

Regeneron将获得10亿美元的预付款，并有望在未来获得高达70亿美元的里程碑式付款；两家公司将均摊开发和商业化成本，并平分任何未来利润。

Sanofi and Regeneron to host a conference call for investors and analysts today at 14:00 CET/8:00am ET

赛诺菲和再生元将于今日欧洲中部时间14:00/美国东部时间上午8:00为投资者和分析师举行电话会议

Paris and Tarrytown, NY, October 1, 2026.

巴黎及纽约州塔里敦，2026年10月1日。

Sanofi and Regeneron Pharmaceuticals, Inc. today announce an expansion of their longstanding antibody collaboration, adding multiple next-generation, long-acting antibodies to the Alliance that has jointly established Dupixent® (dupilumab) as the world-leading treatment for diseases driven by type 2 inflammation.

赛诺菲和再生元制药公司今日宣布扩大其长期抗体合作，向联盟中添加多种下一代长效抗体。该联盟已共同将 Dupixent®（度普利尤单抗）确立为全球领先的 2 型炎症驱动疾病治疗药物。

The agreement builds on the companies' more than 20-year collaboration, through which more than 1.5 million people are currently receiving Dupixent across nine indications, making it one of the most widely used antibody medicines in the world..

该协议建立在两家公司二十余年的合作基础之上。通过这一合作，目前已有超过150万患者在九个适应症上接受Dupixent（度普利尤单抗）治疗，使其成为全球使用最广泛的抗体药物之一。

“This is a deliberate first step in igniting Sanofi’s innovation engine. Our longstanding Alliance with Regeneron has transformed the treatment landscape for millions of patients living with diseases driven by type 2 inflammation and created one of the world's leading immunology businesses,”

“这是点燃赛诺菲创新引擎的刻意第一步。我们与再生元长期建立的联盟已经改变了数百万患有由2型炎症驱动疾病的患者的治疗格局，并创建了全球领先的免疫学业务之一。”

said

说

Belén Garijo

贝伦·加里霍

, Chief Executive Officer of Sanofi.

，赛诺菲首席执行官。

“By deepening our collaboration, we will make rapid progress in creating the next generation of meaningful therapies for patients with immune-mediated diseases, while contributing to Sanofi’s long-term future.”

“通过深化我们的合作，我们将为免疫介导疾病患者快速推进下一代有意义疗法的开发，同时为赛诺菲的长远未来作出贡献。”

Under the expanded license and collaboration agreement, the companies will co-develop and co-commercialize four new long-acting, Regeneron-invented antibodies targeting interleukin-13 (IL-13), IL-4xIL-13 bispecific, interleukin-4 (IL-4) and interleukin-4 receptor alpha (IL-4Rα). IL-13 antibody REGN20423 is currently in a phase 1 clinical study for atopic dermatitis, and the other three antibodies are expected to enter clinical studies in 2027.

根据扩展的许可与合作协议，双方将共同开发并共同商业化四种由再生元发明的新型长效抗体，分别靶向白细胞介素-13（IL-13）、IL-4xIL-13双特异性抗体、白细胞介素-4（IL-4）以及白细胞介素-4受体α（IL-4Rα）。其中，靶向IL-13的抗体REGN20423目前正处于针对特应性皮炎的1期临床研究阶段，其余三种抗体预计将于2027年进入临床研究。

Regeneron will also have the option to include in the collaboration Sanofi’s lunsekimig, an investigational bispecific Nanobody® VHH therapy targeting TSLP and IL-13, exercisable upon completion of its phase 3 studies for chronic obstructive pulmonary disease..

再生元还将有权选择将赛诺菲的lunsekimig纳入合作范围，lunsekimig是一种在研的双特异性Nanobody® VHH疗法，靶向TSLP和IL-13，该选择权在其完成针对慢性阻塞性肺疾病的III期临床研究后可行使。

“The Regeneron-Sanofi Alliance has been one of the most productive in biopharma history. This agreement builds on that foundation to bring the next generation of immunology medicines to patients even faster,”

“再生元与赛诺菲的联盟一直是生物医药史上最具成效的合作之一。本协议在此基础上进一步推进，旨在以更快的速度将下一代免疫学药物带给患者。”

said

说

Leonard S. Schleifer

伦纳德·S·施莱弗

, MD, PhD, Board co-Chair, President and Chief Executive Officer of Regeneron.

医学博士、哲学博士，Regeneron 公司董事会联席主席、总裁兼首席执行官。

“By expanding our Alliance, we are positioning promising new long-acting antibodies for the kind of rapid, global impact that our shared work on Dupixent has already achieved.”

“通过扩大我们的联盟，我们正在为具有前景的新型长效抗体布局，以期实现与我们在Dupixent（度普利尤单抗）上的合作所已取得的快速、全球性影响相类似的成效。”

Under the terms of the agreement, Regeneron will receive an upfront payment of $1 billion from Sanofi, with the potential for development, regulatory and commercial milestone payments of up to an additional $7 billion. The companies will share development and commercialization costs for the new programs and will split future profits from these potential products 50:50 on a global basis.

根据协议条款，Regeneron 将从 Sanofi 获得10亿美元的预付款，并有可能获得高达70亿美元的额外开发、监管和商业里程碑付款。双方将分担新项目的开发和商业化成本，并在全球范围内按50:50的比例分享这些潜在产品的未来利润。

Regeneron will lead research and development activities, and Sanofi will lead global commercial efforts. The existing profit-sharing agreement regarding Dupixent will not change..

再生元将主导研发活动，赛诺菲将主导全球商业化工作。现有关于度普利尤单抗的利润分享协议保持不变。

“The companies’ clinical and commercial Alliance dates to 2003 and has resulted in multiple approved medicines to date, including Dupixent, which has redefined the standard of care for people with type 2 inflammatory diseases and is now one of the most widely used antibodies for any disease, with over 1.5 million active patients worldwide,” .

“两家公司的临床与商业联盟始于2003年，迄今已促成多种药物获批上市，其中包括Dupixent（度普利尤单抗）。该药重塑了2型炎症性疾病患者的治疗标准，目前已成为全球适用疾病范围最广、使用最广泛的抗体药物之一，全球活跃患者人数超过150万。”

said

说

George D. Yancopoulos

乔治·D·扬科普洛斯

, MD, PhD, Board co-Chair, President and Chief Scientific Officer at Regeneron, and a principal inventor of Dupixent.

，医学博士、哲学博士，董事会联席主席，再生元公司总裁兼首席科学官，Dupixent的主要发明人。

“By combining Regeneron’s world-class scientific discovery and antibody development expertise with Sanofi’s global capabilities and reach, we hope to once again deliver the next wave of innovation in immunology.”

“通过将再生元世界级的科学发现与抗体开发专业知识，与赛诺菲的全球能力与覆盖范围相结合，我们有望再次推动免疫学领域的下一波创新。”

The companies have settled their prior collaboration-related litigation.

这些公司已就此前与合作相关的诉讼达成和解。

Conference call for investors and analysts

面向投资者和分析师的电话会议

Sanofi and Regeneron will host a conference call for investors and analysts today at 14:00 CET/8:00am ET. A presentation will be available for download from the Investor Relations section of sanofi.com and regeneron.com when the conference call starts.

赛诺菲和再生元将于今天中欧时间14:00/美东时间上午8:00为投资者和分析师举行电话会议。电话会议开始时，演示文稿可在sanofi.com和regeneron.com的投资者关系部分下载。

Participants may access the conference call via webcast on the ‘Upcoming Events’ page of Sanofi’s website at

参与者可通过赛诺菲网站“即将举行的活动”页面上的网络直播接入电话会议，网址为

https://www.sanofi.com/en/investors/news-events/upcoming-events

, tab ‘Presentations' and on the 'Investors and Media' page of Regeneron's website at

，以及再生元公司网站“投资者与媒体”页面上的“演示文稿”标签页

https://investor.regeneron.com/events-and-presentations

. To participate via telephone, please register in advance

如需通过电话参会，请提前注册。

at this link

在此链接

。

About Dupixent

关于 Dupixent

Dupixent, which was invented using Regeneron’s proprietary

使用再生元公司专有技术发明的 Dupixent，

VelocImmune® technology

VelocImmune®技术

, is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) pathways and is not an immunosuppressant. The Dupixent development program has shown significant clinical benefit and a decrease in type 2 inflammation in phase 3 studies, establishing that IL-4 and IL-13 are two of the key and central drivers of the type 2 inflammation that plays a major role in multiple related and often co-morbid diseases..

是一种全人源单克隆抗体，可抑制白细胞介素-4（IL-4）和白细胞介素-13（IL-13）通路的信号传导，且不属于免疫抑制剂。Dupixent 研发项目在 III 期临床试验中显示出显著的临床获益，并降低了 2 型炎症水平，从而证实 IL-4 和 IL-13 是 2 型炎症的两个关键核心驱动因子，而 2 型炎症在多种相关且常共存的疾病中起着重要作用。

Dupixent has received regulatory approvals in more than 60 countries in one or more indications including certain patients with atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, prurigo nodularis, chronic spontaneous urticaria, chronic obstructive pulmonary disease, bullous pemphigoid, and allergic fungal rhinosinusitis in different age populations.

Dupixent 已在全球 60 多个国家获得监管批准，适用于一个或多个适应症，涵盖不同年龄人群，包括特应性皮炎、哮喘、慢性鼻-鼻窦炎伴鼻息肉、嗜酸性粒细胞性食管炎、结节性痒疹、慢性自发性荨麻疹、慢性阻塞性肺疾病、大疱性类天疱疮和过敏性真菌性鼻-鼻窦炎等特定患者。

In addition to the currently approved indications, Sanofi and Regeneron are studying dupilumab in a broad range of diseases driven by type 2 inflammation or other allergic processes in phase 3 studies, including chronic pruritus of unknown origin. These potential uses of dupilumab are currently under clinical investigation, and the safety and efficacy in these conditions have not been fully evaluated by any regulatory authority..

除目前获批的适应症外，赛诺菲和再生元正在开展多项III期临床研究，评估度普利尤单抗在由2型炎症或其他过敏过程驱动的广泛疾病中的应用，包括原因不明的慢性瘙痒症。度普利尤单抗的这些潜在用途目前正处于临床研究阶段，其在这类疾病中的安全性和有效性尚未得到任何监管机构的全面评估。

About Regeneron

关于再生元

Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in our laboratories.

再生元（纳斯达克股票代码：REGN）是一家领先的生物技术公司，致力于发明、开发和商业化用于改变重症患者生活的药物。由医师科学家创立并领导，我们拥有将科学成果反复且持续转化为医药产品的独特能力，已促成众多获批疗法及处于开发阶段的产品候选药物，其中绝大多数均源自我们的内部实验室。

Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases..

我们的药物和研发管线旨在帮助患有眼部疾病、过敏性和炎症性疾病、癌症、心血管和代谢性疾病、神经系统疾病、血液系统疾病、感染性疾病以及罕见病的患者。

Regeneron pushes the boundaries of scientific discovery and accelerates drug development using our proprietary technologies, such as

再生元利用我们的专有技术，不断突破科学发现的边界并加速药物开发，例如

VelociSuite

，

which produces optimized fully human antibodies and new classes of bispecific antibodies. We are shaping the next frontier of medicine with data-powered insights from the Regeneron Genetics Center

该平台能够生成优化的全人源抗体以及新型双特异性抗体。我们依托再生元遗传中心的数据驱动洞察，正在塑造医学的下一片前沿领域。

and pioneering genetic medicine platforms, enabling us to identify innovative targets and complementary approaches to potentially treat or cure diseases.

以及开创性的基因医学平台，使我们能够识别创新靶点和互补方法，以潜在地治疗或治愈疾病。

For more information, please visit

更多信息，请访问

www.Regeneron.com

or follow Regeneron on

或在以下平台关注 Regeneron

领英

，

Instagram

，

Facebook

脸书

或

。

About Sanofi

关于赛诺菲

Sanofi is an R&D driven, AI-powered biopharma company committed to improving people’s lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people’s lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time..

赛诺菲是一家以研发为驱动、人工智能赋能的生物制药公司，致力于改善人们的生活并实现强劲增长。我们凭借对免疫系统的深刻理解，研发用于治疗和保护全球数百万人的药物和疫苗，并通过创新的产品管线惠及更多人群。我们的团队秉持一个宗旨：追寻科学奇迹以改善人们的生活；这激励我们应对当今最紧迫的医疗、环境和社会挑战，推动进步，为员工和我们服务的社区带来积极影响。

Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY.

赛诺菲在泛欧交易所（代码：SAN）和纳斯达克（代码：SNY）上市。

Sanofi Media Relations

赛诺菲媒体关系

Sandrine Guendoul

桑德琳·根杜尔

| +33 6 25 09 14 25 |

sandrine.guendoul@sanofi.com

Evan Berland

埃文·伯兰德

| +1 215 432 0234 |

evan.berland@sanofi.com

Léo Le Bourhis

莱奥·勒布尔希

| +33 6 75 06 43 81 |

leo.lebourhis@sanofi.com

Victor Rouault

维克多·鲁奥

| +1 617 356 4751 |

victor.rouault@sanofi.com

Timothy Gilbert

蒂莫西·吉尔伯特

| +1 516 521 2929 |

timothy.gilbert@sanofi.com

Léa Ubaldi

莱娅·乌巴尔迪

| +33 6 30 19 66 46 |

lea.ubaldi@sanofi.com

Laura Romby

劳拉·隆比

| +33 6 74 16 74 29 |

laura.romby@sanofi.com

Ekaterina Pesheva

叶卡捷琳娜·佩舍娃

| +1 410 926 6780 |

ekaterina.pesheva@sanofi.com

Sanofi Investor Relations

赛诺菲投资者关系

Thomas Kudsk Larsen

托马斯·库斯克·拉森

| +44 7545 513 693 |

thomas.larsen@sanofi.com

Alizé Kaisserian

阿利泽·凯瑟里安

| +33 6 47 04 12 11 |

alize.kaisserian@sanofi.com

Keita Browne

凯塔·布朗

| +1 781 249 1766 |

keita.browne@sanofi.com

Nathalie Pham

娜塔莉·范

| +33 7 85 93 30 17 |

nathalie.pham@sanofi.com

Nina Goworek

尼娜·戈沃雷克

| +1 908 569 7086 |

nina.goworek@sanofi.com

Thibaud Châtelet

蒂博·沙泰勒

| +33 6 80 80 89 90 |

thibaud.chatelet@sanofi.com

Yun Li

李云

| +33 6 84 00 90 72 |

yun.li3@sanofi.com

Regeneron Media Relations

再生元媒体关系部

Christina Chan

陈克里斯蒂娜

| +1 914-383-6374 |

christina.chan@regeneron.com

Alexandra Bowie

亚历山德拉·鲍伊

| +1 914-346-0588 |

alexandra.bowie@regeneron.com

Regeneron Investor Relations

再生元投资者关系

Ryan Crowe

瑞安·克劳

+1 914-847-8790

ryan.crowe@regeneron.com

Mark Hudson

马克·哈德森

| +1 914-847-3482 |

mark.hudson@regeneron.com

Sanofi forward-looking statements

赛诺菲前瞻性陈述

This press release contains forward-looking statements within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995, as amended.

本新闻稿包含根据适用证券法律（包括经修订的1995年《私人证券诉讼改革法》）所定义的前瞻性陈述。

Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions, and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future events and economic performance.

前瞻性陈述是指非历史事实的陈述。这些陈述包括预测和估计及其基本假设，有关未来财务业绩、事件、运营、服务、产品开发及潜力的计划、目标、意图和期望的陈述，以及有关未来事件和经济表现的陈述。

Words such as “expect,” “anticipate,” “believe,” “intend,” “estimate,” “plan,” “can,” “contemplate,” “could,” “is designed to,” “may,” “might,” “potential,” “objective,” 'attempt,' “target,” “project,” 'strategy,' 'strive,' 'desire,' “predict,” “forecast,” “ambition,” “guideline,” 'seek,' “should,” “will,” 'goal,' or the negative of these, and similar expressions are intended to identify forward-looking statements.

“预期”、“预计”、“相信”、“打算”、“估计”、“计划”、“能够”、“考虑”、“可能”、“旨在”、“可以”、“或许”、“潜在”、“目标”、“尝试”、“指标”、“预测”、“战略”、“努力”、“期望”、“预言”、“预报”、“雄心”、“指导方针”、“寻求”、“应当”、“将”、“目的”等词语，或这些词语的否定形式，以及类似表述，均用于识别前瞻性陈述。

。

Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements.

尽管赛诺菲管理层认为此类前瞻性陈述中所反映的预期是合理的，但提醒投资者注意，前瞻性信息和陈述受各种风险和不确定性的影响，其中许多难以预测且通常超出赛诺菲的控制范围，可能导致实际结果和发展与前瞻性信息和陈述中明示、暗示或预测的内容存在重大差异。

These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the U.S Food and Drug Administration or the European Medicines Agency, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates; the fact that product candidates if approved may not be commercially successful; unexpected regulatory actions or delays, or government regulation generally; authorities’ decisions regarding whether and when to approve a product candidate; political pressure in the United States to mandate lower drug prices including “most favored nation” pricing for State Medicaid programs; the future approval and commercial success of therapeutic alternatives; Sanofi’s ability to benefit from external growth opportunities, to complete related transactions and/or obtain regulatory clearances, including future clinical data and analysis of existing clinical data relating to the product, including post marketing, unexpected safety, quality.

这些风险和不确定性包括但不限于：研发过程中固有的不确定性；未来的临床数据和分析（包括上市后）；监管机构（如美国食品药品监督管理局或欧洲药品管理局）就任何此类候选产品可能提交的药物、器械或生物制品申请是否批准以及何时批准作出的决定，以及其就标签和其他可能影响此类候选产品可获得性或商业潜力的事项作出的决定；候选产品即使获得批准也可能无法在商业上取得成功的事实；意外的监管行动或延误，或一般的政府监管；监管机构就候选产品是否批准以及何时批准作出的决定；美国在政治层面施压强制降低药品价格，包括为州医疗补助计划实施“最惠国”定价；替代疗法的未来获批情况及商业成功；赛诺菲利用外部增长机会、完成相关交易和/或获得监管批准的能力，包括与产品相关的未来临床数据及对现有临床数据（包括上市后数据）的分析，以及意外的安全性和质量问题。

All trademarks mentioned in this press release are the property of the Sanofi group except for VelociSuite and Regeneron Genetics Center.

本新闻稿中提及的所有商标均为赛诺菲集团的财产，但VelociSuite和Regeneron Genetics Center除外。

Regeneron Forward-Looking Statements and Use of Digital Media

再生元前瞻性声明及数字媒体的使用

This press release includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”), and actual events or results may differ materially from these forward-looking statements.

本新闻稿包含前瞻性陈述，涉及与再生元制药公司（“Regeneron”或“公司”）未来事件及未来表现相关的风险和不确定性，实际事件或结果可能与这些前瞻性陈述存在重大差异。

Words such as “anticipate,” “expect,” “intend,” “plan,” “believe,” “seek,” “estimate,” variations of such words, and similar expressions are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. These statements concern, and these risks and uncertainties include, among others, the nature, timing, and possible success and therapeutic applications of products marketed or otherwise commercialized by Regeneron and/or its collaborators or licensees (collectively, “Regeneron’s Products”) and product candidates being developed by Regeneron and/or its collaborators or licensees (collectively, “Regeneron’s Product Candidates”) and research and clinical programs now underway or planned, including without limitation the research and clinical programs discussed or referenced in this press release such as those evaluating Regeneron-discovered antibodies targeting interleukin-13 (IL-13), interleukin-4 (IL-4), and interleukin-4 receptor alpha (IL-4Rα) as well as a bispecific antibody targeting IL-4xIL-13; the potential for any license, collaboration, or supply agreement, including Regeneron’s amended license and collaboration agreement with Sanofi discussed in this press release, to be cancelled or terminated without realizing the expected benefits of such agreement; uncertainty of the utilization, market acceptance, and/or commercial success of Regeneron’s Products and Regeneron’s Product Candidates and the impa.

“anticipate”（预期）、“expect”（期望）、“intend”（打算）、“plan”（计划）、“believe”（相信）、“seek”（寻求）、“estimate”（估计）等词语及其变体以及类似表述旨在识别此类前瞻性陈述，尽管并非所有前瞻性陈述都包含这些识别性词语。这些陈述涉及（且这些风险和不确定性包括但不限于）以下方面：由再生元（Regeneron）和/或其合作方或被许可方（统称“再生元产品”）已上市或以其他方式商业化的产品，以及由再生元和/或其合作方或被许可方（统称“再生元候选产品”）正在开发的候选产品的性质、时机、可能的成功及治疗应用；目前正在进行或计划中的研究和临床项目，包括但不限于本新闻稿中讨论或提及的研究和临床项目，例如评估再生元发现的靶向白细胞介素-13（IL-13）、白细胞介素-4（IL-4）和白细胞介素-4受体α（IL-4Rα）的抗体，以及靶向IL-4xIL-13的双特异性抗体的项目；任何许可、合作或供应协议（包括本新闻稿中讨论的再生元与赛诺菲（Sanofi）之间经修订的许可与合作协议）可能在未实现该协议预期利益的情况下被取消或终止的风险；再生元产品及再生元候选产品的使用、市场接受度和/或商业成功的不确定性，以及其影响。

(aflibercept) Injection), the ultimate outcome of any such proceedings and investigations, and the impact any of the foregoing may have on Regeneron’s business, prospects, operating results, and financial condition. A more complete description of these and other material risks can be found in Regeneron’s filings with the U.S.

（阿柏西普注射液），任何此类诉讼和调查的最终结果，以及上述事项可能对再生元公司的业务、前景、经营业绩和财务状况产生的影响。有关这些及其他重大风险的更完整描述，请参阅再生元公司向美国提交的备案文件。

Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2025 and its Form 10-Q for the quarterly period ended June 30, 2026. Any forward-looking statements are made based on management’s current beliefs and judgment, and the reader is cautioned not to rely on any forward-looking statements made by Regeneron.

证券交易委员会，包括其截至2025年12月31日的年度10-K表格和截至2026年6月30日的季度10-Q表格。任何前瞻性陈述均基于管理层当前的信念和判断，提醒读者不要依赖再生元公司作出的任何前瞻性陈述。

Regeneron does not undertake any obligation to update (publicly or otherwise) any forward-looking statement, including without limitation any financial projection or guidance, whether as a result of new information, future events, or otherwise..

Regeneron 不承担任何更新（公开或以其他方式）任何前瞻性陈述的义务，包括但不限于任何财务预测或指引，无论是由于新信息、未来事件还是其他原因。

Regeneron uses its media and investor relations website and social media outlets to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Regeneron is routinely posted and is accessible on Regeneron's media and investor relations website (.

再生元利用其媒体与投资者关系网站及社交媒体平台发布关于公司的重要信息，包括可能被视为对投资者具有重大性的信息。有关再生元的财务及其他信息会定期发布，并可在再生元的媒体与投资者关系网站上获取。

https://investor.regeneron.com

) and its LinkedIn page (

）及其领英页面（

https://www.linkedin.com/company/regeneron-pharmaceuticals

）。

Attachment

附件

Press_Release

新闻稿

全球产业链接平台

重庆市两江新区礼嘉金泰智能产业园二期15栋601